1. Introduction to B Cell Lymphoma

  1.1 Outline

    1.1.1 Non-Hodgkin’s Lymphoma

    1.1.2 Hodgkin’s Lymphoma

  1.2 Classification of the B Cell lymphoma

    1.2.1 Diffuse Large B Cell Lymphoma

    1.2.2 Follicular Lymphoma

    1.2.3 Mantle Cell Lymphoma

    1.2.4 Burkitt Lymphoma

  1.3 Stages of B Cell Lymphoma

2. Role of B Cell Receptor for Lymphoma Development

  2.1 Diffuse Large B Cell Lymphoma

  2.2 Mantle Cell Lymphoma

  2.3 Burkitt Lymphoma

3. Non-Hodgkin Lymphoma Risk Factors

  3.1 Overview  of Risk Factors

    3.1.1 Infections

    3.1.2 Weakened Immune System

    3.1.3 Exposure to Radiation

    3.1.4 Exposure to Chemicals

  3.2 Causes of Non-Hodgkin Lymphoma

4. Strategies for B Cell Lymphoma Targeting Therapies

  4.1 Current Strategies

    4.1.1 Bruton’s Tyrosine Kinase (BTK)

    4.1.2 Phosphoinositide 3-Kinase anddelta; (PI3Ks)

    4.1.3 Spleen Tyrosine Kinase (SYK)

  4.2 Next Generation Strategies for the Vaccine Therapy

    4.2.1 Membrane Proteoliposomal Vaccine

    4.2.2 Cytotoxic Therapies

5. Diagnosis of B Cell Lymphoma

  5.1 Traditional Methods of Detection

    5.1.1 Biopsy Method

    5.1.2 Flow Cytometry

    5.1.3 Molecular Genetic Tests

    5.1.4 Positron Emission Tomography (PET) Scan

  5.2 New Insights for Diagnosis of B Cell Lymphoma

    5.2.1 Genomic Studies in the Diagnosis

    5.2.2 Next Generation Sequencing

  5.3 Biomarker in B Cell Malignancies

    5.3.1 MicroRNA-155

    5.3.2 B Cell Markers

6. Approaches for the Treatment B Cell Lymphoma

  6.1 Chemotherapy

  6.2 Radiation Therapy

7. Targeted Therapy Drugs for B Cell Lymphoma

  7.1 Proteasome Inhibitors

  7.2 Anti-CD22 Antibody Epratuzumab

  7.3 Immunomodulators

  7.4 Fostamatinib Disodium (Syk Inhibitor)

  7.5 Membrane Target of Rapamycin (mTOR)

8. Global B Cell Lymphoma Market Overview

  8.1 Current Scenario

  8.2 Prevalence

  8.3 B Cell Lymphoma Clinical Pipeline Overview

9. Global B Cell Lymphoma Market Dynamics

  9.1 Accelerative Parameters

  9.2 Challenges to the Market Growth

10. Global B Cell Lymphoma Market Future Scenario

11. Global B Cell Lymphoma Clinical Pipeline by Company and Phase

  11.1 Research

  11.2 Preclinical

  11.3 Clinical

  11.4 Phase-I

  11.5 Phase-I/II

  11.6 Phase-II

  11.7 Phase-II/III

  11.8 Phase-III

  11.9 Preregistration

  11.10 Registered

12. Marketed B Cell Lymphoma Clinical Insight

  12.1 Rituximab (MabThera and Rituxan)

  12.2 Rituximab Biosimilar (Novex)

  12.3 Rituximab Biosimilar (Maball)

13. Competitive Landscape

  13.1 Abbott Laboratories 

  13.2 Biogen Idec   

  13.3 Celgene Corporation 

  13.4 Genmab        

  13.5 Hetero Drugs 

  13.6 ImmunoGen   

  13.7 Incyte Corporation   

  13.8 mAbxience    

  13.9 Merck 

  13.10 Millennium Pharmaceuticals        

  13.11 Ono Pharmaceutical

  13.12 Sandoz        

  13.13 Seattle Genetics     

  13.14 Xencor        

Figure 1-1: Types of B Cell Lymphoma

Figure 1-2: B Cell Lymphoma Stages

Figure 2-1: B Cell Receptor in Diffuse Large B Cell Lymphoma

Figure 2-2: B Cell Receptor Signaling Pathway in Mantle Cell Lymphoma

Figure 3-1: Risk Factors Associated with B Cell Lymphoma

Figure 4-1: Bruton’s Tyrosine Kinase Pathway for Targeting

Figure 4-2: Phosphoinositide 3-Kinase anddelta; as Targeting Therapy

Figure 4-3: Spleen Tyrosine Kinase for Targeting

Figure 5-1: Traditional Methods for Diagnosis of B Cell Lymphoma

Figure 5-2: Noval Techniques for Detection

Figure 6-1: Approaches for the Treatment of B Cell Lymphoma

Figure 8-1: Global - Non-Hodgkin Lymphoma Market (US$ Billion), 2016 - 2022

Figure 8-2: Global - Hodgkin Lymphoma Market (US$ Million), 2016 - 2022

Figure 8-3: Survival Rate of Non-Hodgkin Lymphoma, % (5, 10, 15 Years)

Figure 8-4: Early Stage and Advance Stage Survival Rate, %

Figure 8-5: Estimated Cases of Non-Hodgkin Lymphoma, 100,000 Persons

Figure 8-6: US - B Cell Lymphoma Incidence

Figure 8-7: UK - Diagnosed Cases in Males and Females

Figure 8-8: UK - Mortality Cases in Males and Females

Figure 8-9: India - Incidence Rate in Males and Females

Figure 8-10: Global - B Cell Lymphoma Clinical Pipeline by Phase (%), 2017 till 2022

Figure 8-11: Global -B Cell Lymphoma Clinical Pipeline by Phase (Number), 2017 till 2022

Figure 8-12: Global - Discontinued and Suspended B Cell Lymphoma Drugs in Clinical Pipeline (%), 2017 till 2022

Figure 8-13: Global - Discontinued and Suspended B Cell Lymphoma Drugs in Clinical Pipeline (Number), 2017 till 2022

Figure 9-1: Market Drivers of B cell Lymphoma

Figure 9-2: Challenges to the Growth of the Market